Buy & Sell Quanta Services Inc (PWR) – Quanta Services Inc Price Today
Key Stats
- $103.83BMarket Cap
- IndustrialsSector
- -12.45%3M Drawdown
- $109.79BEnterprise Value
- 0.06%Dividend Yield
- 19% Buy | 81% SellTrading Activity
- 56 daysTypical Hold Time
Quanta Services Inc (PWR) is currently valued at a market capitalization of $103.83B, with an enterprise value of $109.79B. Over the past 52 weeks, Quanta Services Inc has traded between a low of $348.76 and a high of $785.24, highlighting its annual price range. Over the past three months, Quanta Services Inc has recorded a drawdown of -12.45%, reflecting recent price volatility. Quanta Services Inc offers a dividend yield of 0.06%, with the most recent dividend of $0.11 paid on 02 Apr 26. On average, investors hold Quanta Services Inc for approximately 56 days, indicating typical investor behavior on the platform.
About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Most Recent News
Global Initiative on Loneliness and Connection hosts forum to tackle social division and loneliness worldwide
The Global Initiative on Loneliness and Connection (GILC) convened the 2026 Global Connection Forum on June 17 to address the growing public health crisis of loneliness and social isolation, which contribute to serious health risks and societal divis...
Metastatic prostate cancer market to grow strongly through 2036 with new targeted therapies emerging.
The metastatic prostate cancer market is shifting from traditional hormone therapies to precision, biomarker-driven treatments, including novel PARP inhibitors and PSMA-targeted radioligand therapies. The market, valued at $11.5 billion in 2025 in ma...
Over 30 pharma companies race to develop 35+ lupus nephritis drugs, advancing treatment options globally.
The lupus nephritis clinical trial landscape is rapidly expanding with more than 30 pharmaceutical companies developing over 35 drugs targeting this serious autoimmune kidney condition. Key players like Novartis, Simcere, and Regeneron are advancing ...